Microglial Contribution to Glioma Progression: an Immunohistochemical Study in Eastern India

  • Ghosh, Krishnendu (Immunobiology Lab, Department of Zoology, Panihati Mahavidyalaya) ;
  • Ghosh, Samarendranath (Department of Neurosurgery, Bangur Institute of Neurosciences, School of Tropical Medicine) ;
  • Chatterjee, Uttara (Department of Pathology, SSKM Hospital, IPGME&R, School of Tropical Medicine) ;
  • Chaudhuri, Swapna (Department of Experimental Medicine, School of Tropical Medicine) ;
  • Ghosh, Anirban (Immunobiology Lab, Department of Zoology, Panihati Mahavidyalaya)
  • Published : 2016.06.01

Abstract

Human glioma, arising from glial cells of the central nervous system, accounts for almost 30%of all brain tumours, neoplasms with a poor prognosis and high mortality rates worldwide. In the present study we assessed tissue architectural modifications associated with macrophage lineage cells, controversial major immune effector cells within the brain, in human glioma tissue samples from eastern India. Ethically cleared post-operative human glioma samples from our collaborative neurosurgery unit with respective CT/MRI and patient history were collected from the Nodal Centre of Neurosciences in Kolkata, over 9 months. Along with conventional histopathology, samples were subjected to silver-gold staining and fluorescence tagged immunophenotyping for the detection of electron dense brain macrophage/microglia cells in glioma tissue, followed by immune-phenotyping of cells. With higher grades, CD11b+/Iba-1+ macrophage/microglia architecture with de-structured boundaries of glioma lesions indicated malfunction and invasive effector state. Present study documented a contribution of microglia to glioma progression in Eastern India.

Keywords

Glioma;astrocytoma;silver-gold staining;CD11b;Iba1;microglia

Acknowledgement

Supported by : Council of Scientific and Industrial Research (CSIR)

References

  1. ABadie B, Schartner J (2001). Role of microglia in glioma biology. Microsc Res Tech, 54, 106-11. https://doi.org/10.1002/jemt.1125
  2. Barchana M, Margaliot M, Liphshitz I (2012). Changes in brain glioma incidence and laterality correlates with use of mobile phones . a nationwide population based study in Israel. Asian Pac J Cancer Prev, 13, 5857-63. https://doi.org/10.7314/APJCP.2012.13.11.5857
  3. Bhattacharjee M, Bose I, Sarkar P, et al (2006). A sequential scanning of the immune efficacy in astrocytoma (grade i . grade iii), meningioma and secondary glioma patients with and without therapeutic scheduling. Cancer Invest, 24, 502-13. https://doi.org/10.1080/07357900600814839
  4. CBTRUS statistical report (2011). Primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. source: central brain tumour registry of the united states, hinsdale, IL. Website: www.cbtrus.org.
  5. Chen WJ, He DS, Tang RX, et al (2015). Ki-67 is a valuable prognostic factor in gliomas: evidence from systematic review and meta-analysis. Asian Pac J Cancer Prev, 16, 411-20. https://doi.org/10.7314/APJCP.2015.16.2.411
  6. Chen X, Zhang L, Zhang IY, et al (2014). RAGE Expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res, 74, 7285-97. https://doi.org/10.1158/0008-5472.CAN-14-1240
  7. Coniglio SJ, Segall JE (2013). Molecular mechanism of microglia stimulated glioma invasion. Matrix Biol, 32, 372-80. https://doi.org/10.1016/j.matbio.2013.07.008
  8. Das BR, Tangri R, Ahmad F, et al (2013). Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in indian patients. Asian Pac J Cancer Prev, 14, 7261-4. https://doi.org/10.7314/APJCP.2013.14.12.7261
  9. Dix AR, Brooks WH, Roszman TL, et al (1999). Immune defects observed in patients with primary malignant brain tumours. J Neuroimmunol, 100, 216-32. https://doi.org/10.1016/S0165-5728(99)00203-9
  10. Efird JT (2011). Epidemiology of glioma. in 'glioma: exploring its biology and practical relevance', Ed. Ghosh A. InTech, Rijeka, Croatia, 3-24.
  11. Elliott LH, Brooks WH, Roszman TL (1990). Inability of mitogen activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. J Clin Invest, 86, 80-6. https://doi.org/10.1172/JCI114719
  12. Ghosh A, Chaudhuri S (2010). Microglial Action in Glioma: A Boon Turns Bane. Immunol Lett, 131, 3-9. https://doi.org/10.1016/j.imlet.2010.03.003
  13. Ghosh A, Sarkar S, Dutta S, et al (2004). The First Crosssectional survey on intracranial malignancy in Kolkata, India: reflection of the state of art in southern west bengal. Asian Pac J Cancer Prev, 5, 259-67.
  14. Ghosh P, Mukherjee N, Ghosh K, et al (2015). Prospective microglia and brain macrophage distribution pattern in normal rat brain shows age sensitive dispersal and stabilization with development. Ind J Exp Biol, 53, 561-7.
  15. Khan MK, Hunter GK, Vogelbaum M, et al (2009). Evidencebased adjuvant therapy for gliomas: current concepts and newer developments. Ind J Cancer, 46, 96-107. https://doi.org/10.4103/0019-509X.49147
  16. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
  17. Markovic DS, Vinnakota K, Chirasani S, et al (2009). Glioma induce and exploit microglial MT1-MMP expression for tumor expansion. PNAS, 106, 12530-5. https://doi.org/10.1073/pnas.0804273106
  18. Morioka T, Baba T, Black KL, et al (1992). Inflammatory cell infiltrates vary in experimental primary and metastatic brain tumours. Neurosurgery, 30, 891-6.
  19. Ng K, Kesari S, Carter B, et al (2011). Molecular etiology of glioblastomas: implication of genomic profiling from the cancer genome atlas project. in 'glioma: exploring its biology and practical relevance', Ed. Ghosh A. InTech, Rijeka, Croatia, 25-36.
  20. Penfield W, Cone W (1937). Neuroglia and microglia (the metallic methods). In: Handbook of Microscopical Techniques, Eds. McClung CE, Paul B. Hoeber Inc, New York, 489-521.
  21. Preusser M, de Ribaupierre S, Wohrer A, et al (2011). Current concepts and management of glioblastoma. Ann Neurol, 70, 9-21; https://doi.org/10.1002/ana.22425
  22. Roggendorf W, Strupp S, Paulus W, et al (1996). Distribution and characterization of microglia/macrophages in human brain tumours. Acta Neuropathol, 92, 288-93. https://doi.org/10.1007/s004010050520
  23. Sarkar S, Doring A, Zemp FJ, et al (2014). Therapeutic activation of macrophages and microglia to suppress brain tumorinitiating cells. Nat Neurosci, 17, 46-55. https://doi.org/10.1038/nn.3597
  24. Szulzewsky F, Pelz A, Feng X, et al (2015). Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express gpnmb and spp1. PLoS ONE, 10.
  25. Trabelsi S, Brahim DH, Ladib M, et al (2014). Glioma epidemiology in the Central Tunisian Population: 1993-2012. Asian Pac J Cancer Prev, 15, 8753-7. https://doi.org/10.7314/APJCP.2014.15.20.8753
  26. Wei J, Gabrusiewicz K, Heimberger A (2013). The controversial role of microglia in malignant gliomas. Clin Dev Immunol, 2013, 285246.
  27. Xavier-Magalhaes A, Nandhabalan M, Jones C, et al (2013). Molecular prognostic factors in glioblastoma: state of the art and future challenges. CNS Oncol, 2, 495-510. https://doi.org/10.2217/cns.13.48
  28. Ye XZ, Xu SL, Xin YH, et al (2012). Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol, 189, 444-53. https://doi.org/10.4049/jimmunol.1103248